\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={Development and Validation of Derivative FTIR Spectroscopy for Estimation of Entecavir Monohydrate in its Pure and Pharmaceutical Dosage Forms}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2020 2020-01-15 (revised: 33 Year 2020 15 January 2020)} \def\TheID{\makeatother } \def\TheDate{2020 2020-01-15} \title{Development and Validation of Derivative FTIR Spectroscopy for Estimation of Entecavir Monohydrate in its Pure and Pharmaceutical Dosage Forms} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Ashraf A Khanam} \author[2]{Y Padmavathi} \author[3]{Raghavendra Babu} \affil[1]{ G. Pulla Reddy College of Pharmacy, Osmania University} \renewcommand\Authands{ and } \date{\small \em Received: 16 December 2019 Accepted: 4 January 2020 Published: 15 January 2020} \maketitle \begin{abstract} We developed a unique analytical technique for the evaluation of Entecavir monohydrate (ETV) in its pharmaceutical dosage form using derivative spectroscopy assisted FTIR. This approach requires the formation of solid pellets of Entecavir using potassium bromide (KBr) with the aid of geometrical mixing. The spectra were calculated by direct measurement technique using reduced path length in the absorbance mode, and the equipment was configured to secure it at 8cm-1 resolution. We scanned the spectra between the ranges of 4000 to 400 cm-1. FTIR spectra drug exhibited overlapped functional group peaks with baseline correction at 1631 cm-1 corresponding to C=O stretching. From these FTIR spectra, we detected intense, clear, and proportional second derivative peaks between 1639.38 and 1620.09 cm-1. These peaks, in the range of concentration 12.5-200 ?g/mg, obeyed Beer-Lambert?s law. Therefore, we elected C=O stretching for the quantitative evaluation of Entecavir employing second-order derivative spectroscopy. \end{abstract} \keywords{entecavir monohydrate, FTIR, second derivative FTIR, sandell?s sensitivity, statistical analysis.} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \section[{Introduction}]{Introduction}\par epatitis B is a viral infection worldwide that invades the liver and can provoke both severe and persistent diseases. HBV: Hepatitis B virus transmits sexually, parenterally, or perinatally. HBV chronically infects over 248 million people worldwide \hyperref[b0]{[1]}\hyperref[b1]{[2]} .\par Antivirals are drugs that kill a virus or suppress their capability to reproduce. The focus of antiviral medicine is to reduce symptoms, infectivity, and to minimise the span of illness. Antiviral drugs act at various stages by arresting the cycle of viral replication \hyperref[b3]{[3]} .\par Entecavir Monohydrate: The hydrated form of Entecavir is Entecavir Monohydrate: a synthesized analog of 2'deoxyguanosine and a nucleoside reverse transcriptase inhibitor with selective antiviral action against the hepatitis B virus (Fig. \hyperref[fig_0]{1}). It phosphorylates intracellularly with the dynamic triphosphate form, which contests with deoxyguanosine triphosphate (a natural substrate of the virus hepatitis B reverse transcriptase), suppressing every phase of the enzyme's action; at the same time, it bears no activity against HIV. USFDA authorized it in March 2005. The IUPAC name of Entecavir monohydrate is a 2-amino-9-[(1S, 3R, 4S)-4-hydroxy-3 (hydroxymethyl)-2methylidenecyclopentyl]-1H-purin-6-one; hydrate. Its molecular formula and molecular weight is C 12 H 17 N 5 O 4 and 295.29 g/mole, respectively.\par It's a non-hygroscopic, off white to white powder, practically insoluble in acetonitrile, sparingly soluble in N, N-dimethylformamide, slightly soluble in methanol, ethanol (99.5\%) and water (2.4 mg/ml at pH 7.9, 25°C) {\ref [4]} . Store Entecavir tablets in a tightly closed container at 25° C (77° F); excursions permitted between 15-30° C (59-86° F) \hyperref[b4]{[5]} .\par Technique: Spectroscopy is the measurement of the interaction of light with various materials. To determine a chemical substance, analyze the amount of lightH N H N N N O N H 2 CH 2 O H O H O H 2\par absorbed or emitted by a sample. Infrared spectroscopy (IR spectroscopy) is a technique based on the vibrations of the atoms of a molecule. An infrared spectrum is obtained by passing infrared radiation through a sample and determining what fraction of the incident radiation absorbs at a particular energy. The energy at which any peak in an absorption spectrum appears corresponds to the frequency of vibration of a part of a sample molecule \hyperref[b5]{[6]} .\par Fourier-transform infrared (FTIR) spectroscopy is based on the idea of the interference of radiation between two beams to yield an interferogram. The latter is a signal produced as a function of the change of path length between the two beams. The two domains of distance and frequency are interconvertible by the mathematical method of Fourier-transformation \hyperref[b6]{[7]} .\par Derivative spectroscopy (DS) has been brought in for resolving overlapping peaks. DS approach is extensively adopted to intensify the signal and work out the overlapped peak-signals for its improvements in separating closely adjacent peaks and finding weak peaks covered by sharp peaks. When derivatized, the crests and troughs of the original peak function take hold of zero values, and the inflections are modified into maxima or minima, correspondingly. The curves of derivatization are better structured than the authentic spectra, therefore facilitating very slight distinctions to be singled out.\par Advantages of DS are it clears up opportunities for enhancing selectivity and sensitivity; is employed to detect elements with significant accuracy with no preceding step; is incredibly practical when overlap or interference occurs; it extends a dynamic medium for qualitative and quantitative analyses of mixtures; and it is easy to eliminate specimen turbidity matrix background, to improve spectral details and to get rid of the effect of baseline shifts and baseline tilts \hyperref[b7]{[8]} .\par After reviewing ample of available literature, we planned this work to develop and validate a sensitive second derivative technique based on FTIR, for estimation of Entecavir Monohydrate in its pure and pharmaceutical dosage form . \section[{II.}]{II.} \section[{Method}]{Method} \section[{Materials and Reagents (}]{Materials and Reagents (} \section[{a) Method Development}]{a) Method Development}\par Liquid cell and KBr press were utilized for sampling liquids and solids, respectively. We developed FTIR spectroscopic method using an FTIR instrument with the parameters in Table \hyperref[tab_4]{4}. \section[{ii. Preparation of the working standard mixture}]{ii. Preparation of the working standard mixture}\par From the stock (200 µg/mg), accurately weighed 6.250, 12.500, 25.000, 50.000 mg was taken and diluted to 100 mg with dried KBr to create the eventual concentrations of 12.5, 25, 50, and 100 µg/mg, respectively. We ensured uniform mixing. \section[{iii. Extraction Procedure}]{iii. Extraction Procedure}\par Triturate twenty tablets (X-VIR* manufactured by NATCO Pharma Ltd., containing 1 mg of ETV) after taking their average weight. Then the tablet powder equivalent to 1 tablet was transferred to an Eppendorf tube and dissolved in methanol. It was vortexed for 2 minutes, followed by centrifugation at 5000 rpm for 10 minutes. Then the resulting supernatant was collected and evaporated overnight. The residue was collected (approximately 1 mg when weighed). \section[{iv. Sample Preparation for Pressed Pellet Technique}]{iv. Sample Preparation for Pressed Pellet Technique}\par The complete residue obtained was triturated with 50 mg of KBr to make a pellet of 20 ?g/mg, which we scanned in the absorbance mode, and the peak so recovered was derivatized to second order. We then calculated peak area of the derivatized peak. \section[{v. Sample Preparation for Liquid Sampling Technique}]{v. Sample Preparation for Liquid Sampling Technique}\par Using the above extraction procedure, Entecavir monohydrate was extracted from its marketed formulation. Accurately weighed 1 mg of extract was transferred in a 10 ml volumetric flask, and suitable solvents were added individually in each flask, i.e., methanol, DMSO, methanol in chloroform. \section[{c) Method Validation}]{c) Method Validation}\par The FTIR method was developed and validated for quantitative evaluation of ETV in tablets using the KBr pressed pellet technique corresponding to the ICH guidelines Q2 (R1): Validation of Analytical Procedures: Text and Methodology \hyperref[b33]{[32]} .\par i \section[{. Linearity and Range}]{. Linearity and Range}\par The working standard solutions of ETV were prepared and analyzed in the FTIR instrument. We recorded absorbance of the peaks at 1631cm -1 for standard solutions, and plotted the standard calibration curve between concentration and absorbance. Regression analysis established linearity; It reports the regression equation and the coefficient of determination. \section[{ii. Limit of Detection (LOD) and Limit of Quantification (LOQ)}]{ii. Limit of Detection (LOD) and Limit of Quantification (LOQ)}\par We estimated the responsiveness of suggested technique for measurement of ETV in terms of LOD \& LOQ; and determined it using the standard deviation method. Then calculated, the standard deviation and slope from the calibration curve established for linearity parameter using the below-mentioned formulae: LOD = Sandell's sensitivity, defined as the lightest weight of a material that can be encountered in a column of a unit cross-section. The lowest concentration of ETV (12.5µg/mg) was prepared from the working standard solution (200µg/mg) and scanned several times. We noted the absorbance and calculated the Sandell's sensitivity using the formula given below:?????????????? ? ?? ?????????????????????? (??) = ?????????????????????????? ? µg 100mg ? ???????????????????? ?????????? × 0.001 \section[{iv. Precision}]{iv. Precision}\par To establish precision of the method, we reported its repeatability. They usually use the standard deviation (SD) or percentage relative standard deviation (\% RSD) of a course of evaluations to assess the rigor of a scientific technique. Precision was determined using repeatability, and calculated for only one stage of precision. \section[{Repeatability}]{Repeatability}\par We determined repeatability by analyzing six replicates of 100µg/mg, and calculating their percent relative standard deviation (\% RSD). \section[{v. Accuracy}]{v. Accuracy}\par The accuracy of the method was reported as the percentage recovery of a known added measure of the analyte to a specimen or as the difference between the average value obtained and the accepted true value of a specimen, jointly with an associated confidence interval. \section[{For the drug product}]{For the drug product}\par We determined the accuracy study of drug product by calculating the percentage recovery of the ETV using the standard addition method. By adding known amounts of the standard mixture of ETV (40, 50, and 60 ?g/mg), respectively, to a pre-quantified test mixture of ETV (50 ?g/mg). The calculation of percentage recovery was performed by measuring absorbance and qualifying these amounts into the regression equation of the calibration curve and by calculating the percent relative standard deviation (\% RSD) at each stage.\par vi. Assay of Entecavir Monohydrate tablets Triturate twenty tablets (X-VIR* manufactured by NATCO Pharma Ltd., containing 1 mg of ETV) after taking their average weight. Then the tablet powder equivalent to 1 tablet was transferred to an Eppendorf tube and dissolved in methanol. It was vortexed for 2 minutes, followed by centrifugation at 5000 rpm for 10 minutes. Then the resulting supernatant was collected and evaporated overnight. The residue was collected (approximately 1 mg when weighed). Later, the complete residue was triturated with 50 mg of KBr to make a pellet of 20 ?g/mg, which we scanned in the absorbance mode, and the peak so recovered was derivatized to second order. We then calculated peak area of the derivatized peak. \section[{Results and Discussion}]{Results and Discussion} \section[{a) Development and Optimization of FTIR Method i. Solubility Studies}]{a) Development and Optimization of FTIR Method i. Solubility Studies}\par During developmental studies, we checked the drug solubility in methanol and chloroform and its combination. We found ETV solution of methanol in chloroform [50 µg/ml] to be the most reliable solution for solubility that can be studied on a UV-VIS spectrophotometer, giving ? max at 257 nm. \section[{Solution Preparation}]{Solution Preparation}\par We took 10 mg of ETV along with a few ml of methanol in a volumetric flask, which was sonicated for 2 minutes, and made up to 10 ml with methanol to make methanol stock solution of concentration 1000 µg/ml. Then, 0.1, 0.5, and 1.0 ml of this methanol stock solution were made up to volume in other 10 ml volumetric flasks with chloroform to prepare solutions of 10, 50, and 100 µg/ml concentrations, respectively. An overlay of their spectra in Fig. \hyperref[fig_3]{2}. \section[{ii. Analyte Solution Stability Studies}]{ii. Analyte Solution Stability Studies}\par We found ETV solution to be stable for 1 hour after preparation, and carried out solution stability studies on UV-VIS Spectrophotometer, giving a ? max at 257nm for a concentration of 50 µg/ml. So observed a slight, yet gradual decrease in absorbance in Fig. \hyperref[fig_4]{3} We carried out IR analyses using a Shimadzu 8400S FTIR instrument by pressed pellet technique and liquid sample techniques. FTIR method was developed using two sampling techniques: Liquid sampling and the Pressed Pellet Technique. \section[{iii. Liquid Sampling Technique: (Drug Substance)}]{iii. Liquid Sampling Technique: (Drug Substance)}\par Characteristic functional group peaks were seen in the IR spectra of ETV solution of methanol in chloroform but not in those of methanol or DMSO alone, as shown in Fig. \hyperref[fig_5]{4}, 5 \& 6. Also the required increase in functional group absorbance value with an increase in concentration, for quantitation of ETV, wasn't seen. We did not observe any sharp, functional group peaks in the IR spectra taken in DMSO. We did pelleting by geometric mixing of KBr with ETV. They use KBr press for sampling of solids. The FTIR spectrum of ETV standard exhibited well-defined bands and peak absorbance, which increased proportionally with increasing concentration, as shown in Fig. \hyperref[fig_6]{7}. B Thus, we developed the Derivative FTIR spectroscopic method using a solid pelleting technique on the FTIR spectrophotometer. \section[{v. Sample Preparation}]{v. Sample Preparation}\par Performed various techniques and extraction procedures to achieve a better drug recovery from the tablet powder. \section[{Solid Pelleting Technique (Formulation)}]{Solid Pelleting Technique (Formulation)}\par Trial I: Scooping Method One X-VIR* tablet accurately weighed and finely powdered, was transferred into a vial. We randomly scooped out 10 mg of this powder into an FTIR mortar pestle, and added 100 mg of KBr to make a pellet of concentration 100 ?g/mg. Then scanned this pellet, and the IR spectrum obtained for tablet by the scooping method is as in Fig. 8. Observation: We did not observe any peaks in the region of 1600-1750cm -1 , which indicated the absence of the drug in the scoop taken. Thus, scooping is not a reliable technique for sample preparation from the tablet. \section[{Trail II: Extraction Method [X-VIR* Tablet in Methanol]}]{Trail II: Extraction Method [X-VIR* Tablet in Methanol]}\par One X-VIR* tablet, accurately weighed, powdered finely was transferred into an Eppendorf tube. 1 ml of Methanol was added and centrifuged at 5000 rpm for 10 mins. We obtained a clear, supernatant liquid with a pink layer on top of white precipitate, which was collected in a new Eppendorf tube; kept open overnight for evaporation. The next day, we collected the precipitate in the FTIR mortar, and added 50mg of KBr to make a pellet of concentration 20 ?g/mg. This pellet was scanned to obtain IR spectrum as in Fig. 9. Observation: We observed significant peaks as that of pure ETV. However, all the peaks shifted towards higher wavenumber. We noticed C-O peak at 1685.67 cm -1 instead of 1633.59 cm -1 . The intensity of the peak in X-VIR* Tablet (0.531) was relative to standard ETV (0.403). \section[{Trail III: Extraction Method [X-VIR* Tablet in Methanol in Chloroform]}]{Trail III: Extraction Method [X-VIR* Tablet in Methanol in Chloroform]}\par The Extraction procedure was the same for all solvents, except for a change in:\par 1. Solvent and its volume -0.5 ml of Methanol, 0. \section[{B}]{B}\par However, total volume is constant for the extraction procedure. IR spectrum so obtained is as in Fig. 10. Observation: We observed significant peaks as that of pure ETV. However, all the peaks shifted towards higher wavenumber. We noticed C-O peak at 1689.53 cm -1 instead of 1633.59 cm -1 . The intensity of the peak in X-VIR* Tablet (0.749) was relative to that of standard ETV (0.403). \section[{Trail IV: Extraction Method [X-VIR* Tablet in Ethanol]}]{Trail IV: Extraction Method [X-VIR* Tablet in Ethanol]}\par The extraction procedure was the same for all solvents, except for a change in:\par 1. Solvent and its volume -1.0 ml of Ethanol 2. Precipitate observed -white precipitate However, total volume is constant for the extraction procedure. IR spectrum so obtained is as in Fig. 11. Observation: We observed significant peaks as that of pure ETV. All the peaks shifted towards higher wave number. We noticed C-O at 1689.53 cm -1 instead of 1633.59 cm -1 . The intensity of the peak in X-VIR* Tablet (0.434) was relative to standard ETV (0.403). \section[{vi. Liquid Sampling Technique: (Formulation)}]{vi. Liquid Sampling Technique: (Formulation)}\par One tablet was weighed accurately, finely powdered, and extracted using 1 ml of Methanol. We took 1.0 ml of supernatant liquid in a 10 ml volumetric flask, and made up the volume with methanol to make a stock solution of 100?g/ml. It gave high-intensity peaks. The peak at 1708.81cm -1 may be due to C=O stretch, as shown in Fig. 12. From the stock solution, 0.1, 1.0 and 5.0 ml was taken into different 10 ml volumetric flasks, and the volume was made up with chloroform to make the solutions of concentration 1, 10 and 50?g/ml respectively. Their spectra so obtained are shown in Fig. \hyperref[fig_4]{13}, 14 \& 15 correspondingly. Peaks at 1600.81cm -1 and 1710.74 cm -1 may be due to C=O stretch. These graphs were studied as obtained for the above solutions in various concentrations. Scans for liquid sampling cell were measured in transmittance mode, to get better results. The graphs were not clear.\par They exhibited very high transmittance values at most concentrations. Also, functional group shifts were observed, most likely due to the interface from excipients. \hyperref[tab_10]{6}) The band chosen for quantization should be in a region of the spectrum free from absorption by other possible components of the sample. So we selected the following parameters to get better peaks that can be derivatized to estimate the amount of Entecavir Monohydrate present in the sample taken (Table \hyperref[tab_11]{7}). Entecavir monohydrate IR spectrum showed peaks at 1631cm -1 , 3112cm -1 , 3186cm -1 , and 3446cm -1 corresponding to the C-O stretch, primary amine's two N-H stretches and free O-H stretch, respectively. Among these, the C-O group showed a clear and intense peak, which increased linearly as the concentration was increased. Hence, we selected the C-O group for the quantitative evaluation of Entecavir monohydrate. \section[{vii. Comparative Study of Sample Preparation (Table}]{vii. Comparative Study of Sample Preparation (Table} \section[{ix. Verification of Beer's Law}]{ix. Verification of Beer's Law}\par We observed a linear and proportional correlation linking the concentration, and absorbance in \section[{b) Validation of Developed FTIR Method for Quantitative Estimation of Entecavir Monohydrate}]{b) Validation of Developed FTIR Method for Quantitative Estimation of Entecavir Monohydrate}\par We performed the validation for this originated FTIR approach as per ICH Q2 (R1) guidelines, and found all the specifications to be within allowable limits. \section[{i. Linearity of ETV}]{i. Linearity of ETV}\par Working standard solutions of ETV were prepared and analyzed in the investigational concentration range of 12.5-200 µg/mg, as shown in Fig 17-21 and Table \hyperref[tab_13]{9}. We recorded the peak area of the second-order derivative of the C=O peak at 1631cm -1 for the standard solutions. The standard calibration curve was plotted between concentration and peak area to establish linearity by regression analysis, as shown in Fig. \hyperref[fig_0]{16}, Table \hyperref[tab_12]{8}. Corrected value: Yes Equation:\par Corr. Area = -4.642E-2 -1.474E-3 * c\textasciicircum 1, r = 0.992494\par We found the response of the drug to be linear in the investigational concentration range 12.5-200 ?g/mg by acquiring the regression equation, y = 0.0015x + 0.0387, and coefficient of determination, R 2 = 0.9999 for the second derivative of obtained spectra in absorbance mode. ETV obeyed Beer -Lambert's law in the investigational concentration range. \section[{ii. Limit of Detection (LOD) and Limit of quantitation (LOQ) of ETV}]{ii. Limit of Detection (LOD) and Limit of quantitation (LOQ) of ETV}\par We estimated the sensitivity of the proposed method for measurement of ETV for both UV and Derivative FTIR values in terms of LOD \& LOQ, which were determined using the standard deviation method. Standard deviation (??) and slope (??) were calculated from the calibration curve for linearity of each method, respectively, as shown in Table \hyperref[tab_14]{10}. We found the LOD and the LOQ values to be 3.29 and 9.96 µg/mg, respectively, which indicates the sensitivity of the method.\par iii. Sandell's Sensitivity The Sandell's sensitivity was calculated based on the absorbance value of the lowest concentration, 12.5 µg/mg when scanned several times and derivatized to second order. We noted the absorbance(s) and found the Sandell's sensitivity to be 0.0437 µg/cm 2 /0.001 Abs unit. \section[{iv. Precision}]{iv. Precision}\par We reported the precision of the originated analytical technique in terms of repeatability, which was determined by analyzing 6 replicates at 100\% concentration [100?g/mg] of ETV to obtain spectra from IR Solution software in second derivative mode. Later, B we calculated the mean, standard deviation, and \%RSD in MS-Excel (Method Precision). Finally, we calculated the percentage relative standard deviation (\%RSD) and found it to be within limits (NLT 2.0\% and NMT 10.0\%) \hyperref[b33]{[32]} , as shown in Table \hyperref[tab_15]{11} and Fig. 22. Hence the method is repeatable and precise. To check system precision, we scanned one sample of ETV at 100\% concentration [100 ?g/mg] six times, and found the \%RSD to be within limits (NMT 2.0\%) \hyperref[b33]{[32]} , as shown in Table \hyperref[tab_16]{12} and Fig. 23. Hence the system is capable of giving precise results. We carried out an accuracy study by calculating the percent recovery of ETV by the standard addition method. Known amounts of standard ETV (40, 50, and 60?g/mg) were added to a pre-quantified test mixture of X-VIR* tablet extract (50 ?g/mg). The percent recovery was calculated by measuring the peak area, and fitting these values into the regression equation of the calibration curve. Concentrations recovered are tabulated in Table \hyperref[tab_3]{13}.\par Table \hyperref[tab_3]{13}: Recovery data for Entecavir Monohydrate drug product (X-VIR* tablets) \section[{*Average of 3 determinations}]{*Average of 3 determinations}\par Overlay spectra of the three recovery curves of Entecavir Monohydrate recovered from the marketed formulation of X-VIR* tablets at the spike levels of 80-120\% in absorbance and second derivative modes are as in Fig. 24 We found the method to be accurate for the determination of Entecavir monohydrate in tablets as the percentage recovery values calculated were found to be within the acceptable limits (100±2\%) \hyperref[b33]{[32]} . \section[{vi. Assay}]{vi. Assay}\par Assay means to provide an exact result that allows an accurate statement on the content or potency of the analyte in a sample. -ICH Q2(R1). The peak area value of the specimen scanned in absorbance mode (Fig. 26) and derivatized to second-order (Fig. 27) was substituted into the regression equation of the calibration curve to obtain its concentration, which we used ultimately to calculate its purity as shown in Table \hyperref[tab_18]{14}. The shift in the absorbance value of the C=O peak from 1631.67 cm -1 to 1689.53 cm -1 is due to the interference of excipients in the marketed formulation {\ref [34]} .\par IV. \section[{Comparitive Analysis}]{Comparitive Analysis}\par To ensure this developed technique is appropriate and superior to existing analytical methods, we performed a few validation parameters on previously developed and published UV and HPLC methods from various journals and Indian pharmacopeia {\ref [35,} {\ref 36]} . The results so obtained were compared with the current derivative FTIR method to prove this new technique is equally good. \section[{a) Linearity of ETV on UV-VIS Spectrophotometer}]{a) Linearity of ETV on UV-VIS Spectrophotometer}\par The linearity was established on UV-VIS Spectrophotometer by performing linear analysis for the calibration curve constructed between concentration and absorbance. The investigational concentration ranges of 15-50 µg/ml (Fig. 29) were found to be linear and obeying Beer -Lambert's Law, as shown in Table \hyperref[tab_19]{15} and Fig. 28. We found the regression equation to be y = 0.0232x + 1.5492 with correlation coefficient, R 2 = 0.9942. b) UV-VIS Spectroscopy v/s Second Derivative FTIR Spectroscopy (Table \hyperref[tab_20]{16}) We dissolved the pure drug of ETV and the residue obtained from extracted X-VIR* tablet in methanol (1000 µg/ml) and spiked it in 10 ml chloroform to obtain the standard stock solutions of 100 µg/ml each, respectively.\par Then we injected these solutions into the RP-HPLC, and the overlay chromatogram so obtained is shown in Fig. 30, We found the mean value of \% purity for the second derivative FTIR method to be 99.75\% and that of RP-HPLC to be 90.04\% from Table \hyperref[tab_22]{18}. We calculated the assay result of Entecavir monohydrate by both methods. Statistical analysis of the outcomes of the two techniques showed a significant difference between the techniques at a significance level ( ??) of 5\% (t calculated > t critical ). Furthermore, the amount of Entecavir monohydrate calculated by both procedures was within the range between 90 -110\%. Since variances of the population were not known and size of the samples was small, t-test for difference in means was adopted assuming the populations to be normal and we worked out the test statistic t under the given formula: As our hypothesis was two-sided, we applied a two-tailed test for determining the rejection regions at 5 percent level which came to as under, using the table of t-distribution for 4 degrees of freedom:R: | t | > 2.776\par The observed value of t was 3.453 (t calculated > t critical ), which falls in the region of rejection of our hypothesis. So we reject our hypothesis of both methods not being significantly different and conclude that the two ways to determine the percentage purity of Entecavir monohydrate differ significantly.\par V. \section[{Conclusion}]{Conclusion}\par The developed method for estimation of Entecavir monohydrate is based on the application of FTIR with derivative assistance by using the solid pellet technique, which was compared statistically with the pharmacopoeial method (HPLC), and the results revealed that the developed new technique was significantly different. Hence it proves good applicability. It fulfilled all validation requirements in a range of concentrations, and they can use this technique as an alternative to the official methods.\par It is suitable for quality control of both pure and marketed solid dosage form, and similar methods can be developed for other categories of drugs for their estimation in the formulations. \begin{figure}[htbp] \noindent\textbf{1}\includegraphics[]{image-2.png} \caption{\label{fig_0}Figure 1 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{}\includegraphics[]{image-3.png} \caption{\label{fig_1}}\end{figure} \begin{figure}[htbp] \noindent\textbf{}\includegraphics[]{image-4.png} \caption{\label{fig_2}}\end{figure} \begin{figure}[htbp] \noindent\textbf{2}\includegraphics[]{image-5.png} \caption{\label{fig_3}Figure 2 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{3}\includegraphics[]{image-6.png} \caption{\label{fig_4}Figure 3 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{4}\includegraphics[]{image-7.png} \caption{\label{fig_5}Figure 4 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{7}\includegraphics[]{image-8.png} \caption{\label{fig_6}Figure 7 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{1} \par \begin{longtable}{P{0.85\textwidth}} 2 \& 3)\end{longtable} \par \caption{\label{tab_0}Table 1 ,}\end{figure} \begin{figure}[htbp] \noindent\textbf{1} \par \begin{longtable}{P{0.09251700680272108\textwidth}P{0.44523809523809527\textwidth}P{0.3122448979591837\textwidth}} S. No.\tabcellsep Chemicals\tabcellsep Category\\ 1.\tabcellsep Potassium Bromide Anhydrous\tabcellsep IR Grade\\ 2.\tabcellsep Dimethyl Sulfoxide\tabcellsep AR Grade\\ 3.\tabcellsep Chloroform\tabcellsep HPLC Grade\\ 4.\tabcellsep Water\tabcellsep HPLC Grade\\ 5.\tabcellsep Methanol\tabcellsep HPLC Grade\end{longtable} \par \caption{\label{tab_1}Table 1 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{2} \par \begin{longtable}{P{0.040052356020942405\textwidth}P{0.3293193717277487\textwidth}P{0.48062827225130894\textwidth}} S.No.\tabcellsep Name\tabcellsep Manufacturer/ Supplier\\ 1.\tabcellsep Entecavir Monohydrate (Pure form)\tabcellsep Gift sample from Dr.Reddy's Laboratories, Hyderabad.\\ 2.\tabcellsep X-VIR* Tablets (Marketed Formulation)\tabcellsep Bought from a local pharmacy store\end{longtable} \par \caption{\label{tab_2}Table 2 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{3} \par \begin{longtable}{P{0.0425\textwidth}P{0.2925\textwidth}P{0.29\textwidth}P{0.225\textwidth}} S.No.\tabcellsep Instruments\tabcellsep Make and model\tabcellsep Software\\ 1.\tabcellsep FTIR Spectrophotometer\tabcellsep Shimadzu -8400S\tabcellsep IR Solutions (Ver. 1.21)\\ 2.\tabcellsep UV-VIS Spectrophotometer\tabcellsep Shimadzu -1800\tabcellsep UV Probe (Ver. 2.43)\\ 3.\tabcellsep HPLC\tabcellsep Shimadzu -LC-20AT\tabcellsep LC Solution (Ver. 1.25)\\ 4.\tabcellsep Electronic Balance\tabcellsep Shimadzu -BL220H\tabcellsep -NA -\\ 5.\tabcellsep Ultra-Sonic Bath Sonicator\tabcellsep PCI Analytics -6.5 li200H\tabcellsep -NA -\\ 6.\tabcellsep Hot Air Oven\tabcellsep BTI Mumbai -105\tabcellsep -NA -\end{longtable} \par \caption{\label{tab_3}Table 3 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{4} \par \begin{longtable}{P{0.3084831460674157\textwidth}P{0.25213483146067417\textwidth}P{0.28938202247191014\textwidth}} S.No.\tabcellsep Parameter\tabcellsep Selected Condition\\ 1.\tabcellsep Selection of Measurement Mode\tabcellsep Absorbance Mode\\ 2.\tabcellsep Selection of Beam\tabcellsep Internal\\ 3.\tabcellsep Selection of Detector\tabcellsep Standard DLATGS detector\\ 4.\tabcellsep Selection of Mirror Speed\tabcellsep 2.8 mm/sec\\ 5.\tabcellsep Selection of Sampling Technique\tabcellsep Pressed Pellet technique\\ 6.\tabcellsep Selection of Apodization\tabcellsep Happ-Genzel\\ 7.\tabcellsep Selection of solvent (based on IR transparency window)\tabcellsep For Liquid: Chloroform, Dimethyl sulfoxide and methanol For Solid: Potassium Bromide\\ 8.\tabcellsep Analysis of IR Spectra for Functional Group Assessment\tabcellsep ETV IR Spectrum: Peak at 1631 cm -1 , C-O stretch Clear, intense peak, increased linearly with concentration.\\ \multicolumn{2}{l}{b) Method Optimization}\tabcellsep \\ \multicolumn{2}{l}{i. Preparation of standard stock of Entecavir}\tabcellsep \\ \multicolumn{2}{l}{monohydrate}\tabcellsep \\ \multicolumn{2}{l}{Accurately weighed 40 mg of the Entecavir}\tabcellsep \\ \multicolumn{2}{l}{monohydrate was geometrically mixed with 200 mg of}\tabcellsep \\ \multicolumn{2}{l}{dried KBr to form the stock of 200?g/mg. Mix the}\tabcellsep \\ \multicolumn{2}{l}{triturate well, such that each pellet formed contained}\tabcellsep \\ \multicolumn{2}{l}{the uniformly distributed drug.}\tabcellsep \end{longtable} \par \caption{\label{tab_4}Table 4 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{5} \par \begin{longtable}{P{0.85\textwidth}} Year 2020\\ 16\end{longtable} \par \caption{\label{tab_5}Table 5 .}\end{figure} \begin{figure}[htbp] \noindent\textbf{5} \par \begin{longtable}{P{0.10714285714285714\textwidth}P{0.39999999999999997\textwidth}P{0.34285714285714286\textwidth}} S.No.\tabcellsep Time Point (hours)\tabcellsep Absorbance (A) at 257nm\\ 1.\tabcellsep 0 -Black\tabcellsep 2.265\\ 2.\tabcellsep 0.5 -Red\tabcellsep 2.258\\ 3.\tabcellsep 1 -Blue\tabcellsep 2.238\\ 4.\tabcellsep 3 -Pink\tabcellsep 2.102\\ 5.\tabcellsep 4 -Green\tabcellsep 2.050\end{longtable} \par \caption{\label{tab_6}Table 5 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{} \par \begin{longtable}{P{0.39211309523809523\textwidth}P{0.10625\textwidth}P{0.03288690476190476\textwidth}P{0.010119047619047618\textwidth}P{0.08095238095238094\textwidth}P{0.22767857142857142\textwidth}} \tabcellsep 3.495\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \tabcellsep 3.000\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \tabcellsep 2.000\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Abs.\tabcellsep 1.000\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \tabcellsep 0.000\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \multicolumn{5}{l}{-1.000 Figure 5: IR spectrum of Entecavir Monohydrate pure in DMSO by liquid sampling technique -1.333 (Transmittance mode)}\tabcellsep Year 2020\\ \tabcellsep 236.64 250.00\tabcellsep \multicolumn{2}{l}{300.00}\tabcellsep 350.00\tabcellsep 17\\ \tabcellsep \tabcellsep nm.\tabcellsep \tabcellsep \tabcellsep \\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Volume XX Issue V Version I\\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep D D D D ) B\\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep (\\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Medical Research\\ 75 100 \%T\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Global Journal of\\ 50\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ 4000\tabcellsep 3000\tabcellsep 2000\tabcellsep 1500\tabcellsep 1000\tabcellsep 500\\ \multicolumn{2}{l}{ECMHT200LIQB}\tabcellsep \tabcellsep \tabcellsep \tabcellsep 1/cm\\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{© 2020 Global Journals}\end{longtable} \par {\small\itshape [Note: Figure 6: IR spectrum of Entecavir Monohydrate pure in methanol in chloroform by liquid sampling technique (Transmittance mode) iv. Pressed Pellet / Solid Pelleting Technique: (Drug Substance)]} \caption{\label{tab_7}}\end{figure} \begin{figure}[htbp] \noindent\textbf{} \par \begin{longtable}{P{0.27213438735177864\textwidth}P{0.13102766798418972\textwidth}P{0.02351778656126482\textwidth}P{0.06383399209486165\textwidth}P{0.02351778656126482\textwidth}P{0.06383399209486165\textwidth}P{0.02351778656126482\textwidth}P{0.02351778656126482\textwidth}P{0.05039525691699604\textwidth}P{0.03695652173913043\textwidth}P{0.02351778656126482\textwidth}P{0.02351778656126482\textwidth}P{0.07055335968379448\textwidth}P{0.020158102766798417\textwidth}} \tabcellsep 100\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \tabcellsep \%T\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \tabcellsep 90\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \tabcellsep 80\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Year 2020\tabcellsep 4000\tabcellsep \tabcellsep \multicolumn{2}{l}{3000}\tabcellsep 2000\tabcellsep \tabcellsep \tabcellsep \multicolumn{4}{l}{1500}\tabcellsep 1000\tabcellsep 5\\ 18\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Volume XX Issue V Version I\tabcellsep 0 50 100 \%T\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ D D D D )\tabcellsep 4000\tabcellsep \tabcellsep \multicolumn{2}{l}{3000}\tabcellsep 2000\tabcellsep \tabcellsep \tabcellsep \tabcellsep \multicolumn{4}{l}{1500}\tabcellsep 1000\\ (\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Medical Research\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Global Journal of\tabcellsep 50 \%T\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \tabcellsep 25\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep 894.91\\ \tabcellsep 0\tabcellsep 3446.56\tabcellsep 3186.18\tabcellsep 3112.89\tabcellsep 1724.24\tabcellsep 1687.60\tabcellsep 1631.67\tabcellsep 1600.81\tabcellsep 1577.66\tabcellsep 1541.02\tabcellsep 1487.01\tabcellsep 1400.22\\ \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{3000}\tabcellsep 2000\tabcellsep \tabcellsep \tabcellsep \multicolumn{4}{l}{1500}\tabcellsep 1000\tabcellsep 5\end{longtable} \par \caption{\label{tab_8}}\end{figure} \begin{figure}[htbp] \noindent\textbf{6} \par \begin{longtable}{P{0.026090468497576735\textwidth}P{0.1386914378029079\textwidth}P{0.34604200323101775\textwidth}P{0.33917609046849756\textwidth}} S.No.\tabcellsep Parameters\tabcellsep Solid Pelleting Technique\tabcellsep Liquid Sampling Technique\\ 1.\tabcellsep Sample Preparation\tabcellsep Tricky and requires good skill as the quantity is too small\tabcellsep Requires skill, however is comparatively easy\\ 2.\tabcellsep Mode of Measurement\tabcellsep Absorbance Mode\tabcellsep Transmittance Mode\\ 3.\tabcellsep Derivatization\tabcellsep Gives single, almost symmetrical peak\tabcellsep Gives Bifurcated, unsymmetrical peak\\ 4.\tabcellsep Intensity\tabcellsep Within normal range, when compared to standard ETV\tabcellsep Very high intensities, when compared to standard ETV\\ 5.\tabcellsep Sensitivity\tabcellsep Very High\tabcellsep Fairly Acceptable\\ 6.\tabcellsep Selectivity\tabcellsep High, improved peak shape\tabcellsep Low, distorted peaks\\ 7.\tabcellsep Stability\tabcellsep Partial decomposition of pellets\tabcellsep Complete decomposition of solution\end{longtable} \par \caption{\label{tab_10}Table 6 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{7} \par \begin{longtable}{P{0.21715328467153286\textwidth}P{0.272992700729927\textwidth}P{0.3598540145985401\textwidth}} S.No.\tabcellsep Parameter\tabcellsep Optimized Condition\\ 1.\tabcellsep Frequency Range\tabcellsep 400-4000 cm -1\\ 2.\tabcellsep Maximum No. of Scans\tabcellsep 10 (for better S/N ratio)\\ 3.\tabcellsep Resolution\tabcellsep 8 cm -1 (for better peak-to-peak separation)\\ 4.\tabcellsep Beer-Lambert's Concentration Range\tabcellsep 12.5-200 ?g/mg\\ \multicolumn{2}{l}{viii. IR Spectrum Analysis for Functional Group}\tabcellsep \\ Assessment\tabcellsep \tabcellsep \end{longtable} \par \caption{\label{tab_11}Table 7 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{8} \par \begin{longtable}{P{0.24205298013245033\textwidth}P{0.24205298013245033\textwidth}P{0.3658940397350993\textwidth}} S.No.\tabcellsep Concentration (µg/mg)\tabcellsep *Peak Area [1639.38-1620.09 cm -1 ]\\ 1.\tabcellsep 12.5\tabcellsep 0.0554\\ 2.\tabcellsep 25.0\tabcellsep 0.0751\\ 3.\tabcellsep 50.0\tabcellsep 0.1134\\ 4.\tabcellsep 100.0\tabcellsep 0.1859\\ 5.\tabcellsep 200.0\tabcellsep 0.3306\\ \multicolumn{2}{l}{*Average of 3 determinations}\tabcellsep \end{longtable} \par \caption{\label{tab_12}Table 8 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{9} \par \begin{longtable}{P{0.07243478260869565\textwidth}P{0.5927826086956521\textwidth}P{0.00591304347826087\textwidth}P{0.00591304347826087\textwidth}P{0.04582608695652174\textwidth}P{0.10347826086956521\textwidth}P{0.00591304347826087\textwidth}P{0.00591304347826087\textwidth}P{0.00591304347826087\textwidth}P{0.00591304347826087\textwidth}} \tabcellsep \multicolumn{2}{l}{ECMHP12 Overlay\textbackslash ECMHP12 ECMHP25 Overlay\textbackslash ECMHP25}\tabcellsep \tabcellsep \tabcellsep 1631.\tabcellsep \tabcellsep \\ \tabcellsep \multicolumn{3}{l}{ECMHP50d Overlay\textbackslash ECMHP50d}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \tabcellsep \multicolumn{3}{l}{ECMHP100d Overlay\textbackslash ECMHP100d}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ 3\tabcellsep \multicolumn{3}{l}{ECMHP200 Overlay\textbackslash EECMHConc2}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Abs\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep 1633.59 1633.59 1631.671631.67\tabcellsep \tabcellsep \\ \multicolumn{2}{l}{Abs/(1/cm)\textasciicircum 2}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ 0.025\tabcellsep \multicolumn{3}{l}{ECMHP200\textbackslash Second Derivative ECMHP100\textbackslash Second Derivative ECMHP50\textbackslash Second Derivative ECMHP25\textbackslash Second Derivative ECMHP12\textbackslash Second Derivative}\tabcellsep 1635.52 1639.38 1639.38 1639.38\tabcellsep 1620.09 1618.17 1620.09 1620.09\tabcellsep \tabcellsep \\ 0\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ -0.025\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ -0.05\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \tabcellsep 1750\tabcellsep 1700\tabcellsep \multicolumn{2}{l}{1650}\tabcellsep 1600\tabcellsep 1550\tabcellsep 1500\tabcellsep 1450\tabcellsep 1400\end{longtable} \par \caption{\label{tab_13}Table 9 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{10} \par \begin{longtable}{P{0.4694029850746269\textwidth}P{0.19029850746268656\textwidth}P{0.19029850746268656\textwidth}} Name of the drug\tabcellsep LOD (µg/mg)\tabcellsep LOQ (µg/mg)\\ Entecavir Monohydrate\tabcellsep 3.29\tabcellsep 9.96\end{longtable} \par \caption{\label{tab_14}Table 10 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{11} \par \begin{longtable}{P{0.2167785234899329\textwidth}P{0.10268456375838926\textwidth}P{0.25671140939597314\textwidth}P{0.22248322147651006\textwidth}P{0.05134228187919463\textwidth}} \multicolumn{2}{l}{S.No. Concentration (g/mg)}\tabcellsep Peak Area\tabcellsep Mean*±Standard Deviation\tabcellsep \%RSD\\ 1.\tabcellsep 100\tabcellsep 0.2296\tabcellsep \\ 2.\tabcellsep 100\tabcellsep 0.2242\tabcellsep \\ 3.\tabcellsep 100\tabcellsep 0.2527\tabcellsep \\ \tabcellsep \tabcellsep \tabcellsep 0.2370 ± 0.0124\tabcellsep 5.23\\ 4.\tabcellsep 100\tabcellsep 0.2556\tabcellsep \\ 5.\tabcellsep 100\tabcellsep 0.2323\tabcellsep \\ 6.\tabcellsep 100\tabcellsep 0.2275\tabcellsep \end{longtable} \par \caption{\label{tab_15}Table 11 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{12} \par \begin{longtable}{P{0.07203389830508473\textwidth}P{0.547457627118644\textwidth}P{0.07203389830508473\textwidth}P{0.06338983050847458\textwidth}P{0.07347457627118643\textwidth}P{0.021610169491525423\textwidth}} \multicolumn{2}{l}{Abs/(1/cm)\textasciicircum 2}\tabcellsep \tabcellsep \tabcellsep \\ \tabcellsep \multicolumn{2}{l}{Repeatability 1\textbackslash Second Derivative}\tabcellsep \tabcellsep \\ \tabcellsep \multicolumn{2}{l}{Repeatability 2\textbackslash Second Derivative}\tabcellsep \tabcellsep \\ 0.02\tabcellsep \multicolumn{2}{l}{1639.38 1639.38 1639.38 1639.38 1639.38 1639.38 Repeatability 3\textbackslash Second Derivative Repeatability 4\textbackslash Second Derivative Repeatability 5\textbackslash Second Derivative Repeatability 16\textbackslash Second Derivative}\tabcellsep \tabcellsep 1620.09 1620.09 1620.09 1620.09 1620.09 1620.09\\ 0\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ -0.02\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \tabcellsep 1642.5\tabcellsep 1635\tabcellsep 1627.5\tabcellsep 1620\tabcellsep 1612.5\\ S.No.\tabcellsep Concentration ( g/mg)\tabcellsep Peak Area\tabcellsep \multicolumn{2}{l}{Mean*±Standard Deviation}\tabcellsep \%RSD\\ 1\tabcellsep 100\tabcellsep 0.2381\tabcellsep \tabcellsep \\ 2\tabcellsep 100\tabcellsep 0.2389\tabcellsep \tabcellsep \\ 3 4\tabcellsep 100 100\tabcellsep 0.2365 0.2317\tabcellsep \multicolumn{2}{l}{0.2365 ± 0.027}\tabcellsep 1.16\\ 5\tabcellsep 100\tabcellsep 0.2342\tabcellsep \tabcellsep \\ 6\tabcellsep 100\tabcellsep 0.2394\tabcellsep \tabcellsep \end{longtable} \par \caption{\label{tab_16}Table 12 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{} \par \begin{longtable}{P{0.4393551688843398\textwidth}P{0.29493346980552715\textwidth}P{0.04089048106448311\textwidth}P{0.07482088024564994\textwidth}} \multicolumn{2}{l}{Abs/(1/cm)\textasciicircum 2}\tabcellsep \\ \tabcellsep Repeatability 1a\textbackslash Second Derivative\tabcellsep \\ \tabcellsep Repeatability 1b\textbackslash Second Derivative\tabcellsep \\ 0.02\tabcellsep Repeatability 1c\textbackslash Second Derivative 1639.38 1639.38 1639.38 1639.38 1639.38 1639.38 Repeatability 1d\textbackslash Second Derivative Repeatability 1e\textbackslash Second Derivative Repeatability 1f\textbackslash Second Derivative\tabcellsep 1620.09 1620.09 1620.09 1620.09 1620.09 1620.09\\ 0\tabcellsep \tabcellsep \\ -0.02\tabcellsep \tabcellsep \\ \multicolumn{3}{l}{1620 1250 Figure 24: 1612.5 1627.5 1635 1642.5 1650 1000 1500 1750 2000 2500 3000 3500 4000 -0 0.5 1 Abs 80\%\textbackslash 80\% 100\%\textbackslash 120\% 120\%\textbackslash 100\% 2. 100 50 50 100 0.1334 3. 120 60 50 110 0.1261 S.No. Spike Level (\%) Concentration of pure ETV added ( g/mg) Concentration of X-VIR tablet extract added (g/mg) Total Concentration ( g/mg) Peak Area* Concentration 750 101.40 99.88 Recovered (\%) 1. 80 40 50 90 0.0975 100.89 Figure 25:}\tabcellsep Year 2020 Global Journal of Medical Research ( D D D D ) B Volume XX Issue V Version I\end{longtable} \par \caption{\label{tab_17}}\end{figure} \begin{figure}[htbp] \noindent\textbf{14} \par \begin{longtable}{P{0.5173913043478261\textwidth}P{0.10625\textwidth}P{0.15706521739130433\textwidth}P{0.06929347826086957\textwidth}} S.No.\tabcellsep Brand Name\tabcellsep Chemical Name\tabcellsep \% Purity*\\ 1.\tabcellsep X-VIR Tablets\tabcellsep Entecavir Monohydrate\tabcellsep 99.75\\ \multicolumn{2}{l}{*Average of 3 determinations}\tabcellsep \tabcellsep \\ \multicolumn{3}{l}{USP drug content limits for commercially available tablets is 98-102\% [33] .}\tabcellsep \end{longtable} \par \caption{\label{tab_18}Table 14 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{15} \par \begin{longtable}{P{0.1451219512195122\textwidth}P{0.25569105691056915\textwidth}P{0.4491869918699187\textwidth}} S.No.\tabcellsep Concentration (µg/ml)\tabcellsep Absorbance *(A) at 257 nm\\ 1.\tabcellsep 15\tabcellsep 1.904\\ 2.\tabcellsep 20\tabcellsep 2.050\\ 3.\tabcellsep 25\tabcellsep 2.102\\ 4.\tabcellsep 30\tabcellsep 2.238\\ 5.\tabcellsep 35\tabcellsep 2.338\\ 6.\tabcellsep 40\tabcellsep 2.471\\ 7.\tabcellsep 45\tabcellsep 2.605\\ 8.\tabcellsep 50\tabcellsep 2.730\end{longtable} \par {\small\itshape [Note: *Average of 3 determinationsFigure 28: Standard calibration curve of ETV [15-50 µg/ml]]} \caption{\label{tab_19}Table 15 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{16} \par \begin{longtable}{P{0.08203285420944559\textwidth}P{0.3857289527720739\textwidth}P{0.17802874743326488\textwidth}P{0.20420944558521562\textwidth}} S.No.\tabcellsep Parameters\tabcellsep UV -VIS Spectroscopy\tabcellsep Second Derivate FTIR Spectroscopy\\ 1.\tabcellsep Concentration Range\tabcellsep 15-50 µg/ml\tabcellsep 12.5-200 µg/mg\\ 2.\tabcellsep Regression Equation (y = mx + c)\tabcellsep y = 0.0232x + 1.5492\tabcellsep y = 0.0015x + 0.0387\\ 3.\tabcellsep Coefficient of Determination (R 2 )\tabcellsep 0.9942\tabcellsep 0.9999\\ 4.\tabcellsep Standard Deviation (STDEV)\tabcellsep 0.285555\tabcellsep 0.111541\\ 5.\tabcellsep Standard Error between Y and X (STEYX)\tabcellsep 0.023520\tabcellsep 0.001457\\ 6.\tabcellsep Slope (??)\tabcellsep 0.023248\tabcellsep 0.001463\\ 7.\tabcellsep Limit of Detection (LOD)\tabcellsep 3.39 µg/ml\tabcellsep 3.29 µg/mg\\ 8.\tabcellsep Limit of Quantitation (LOQ)\tabcellsep 10.12 µg/ml\tabcellsep 9.96 µg/mg\\ \multicolumn{2}{l}{c) Assay of ETV on RP-HPLC}\tabcellsep \tabcellsep \end{longtable} \par \caption{\label{tab_20}Table 16 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{17} \par \begin{longtable}{P{0.07727272727272727\textwidth}P{0.35382775119617227\textwidth}P{0.4188995215311005\textwidth}} S.No.\tabcellsep Parameters\tabcellsep Conditions\\ 1.\tabcellsep Column\tabcellsep Enable-18H C-18 column\\ 2.\tabcellsep Column Dimensions\tabcellsep 250mm × 4.6mm, 5µm\\ 3.\tabcellsep Mobile Phase\tabcellsep Water:Methanol (80:20)\\ 4.\tabcellsep Flow Rate\tabcellsep 1.2 ml/min\\ 5.\tabcellsep Injection Volume\tabcellsep 20 µL\\ 6.\tabcellsep Wavelength\tabcellsep 254 nm\\ 7.\tabcellsep Runtime\tabcellsep 15 minutes\end{longtable} \par \caption{\label{tab_21}Table 17 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{18} \par \begin{longtable}{P{0.85\textwidth}} Development\end{longtable} \par {\small\itshape [Note: *Average of 3 determinations]} \caption{\label{tab_22}Table 18 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{19} \par \begin{longtable}{P{0.45224358974358975\textwidth}P{0.1389423076923077\textwidth}P{0.17708333333333334\textwidth}P{0.08173076923076923\textwidth}} Method\tabcellsep Mean of percentage purity\tabcellsep Standard deviation of individual data\tabcellsep Size of sample\\ Second Derivative FTIR\tabcellsep ??? 1 = 99.75\tabcellsep ?? 1 2 = 0.808\tabcellsep ?? 1 = 3\\ RP-HPLC\tabcellsep ??? 2 = 90.04\tabcellsep ?? 2 2 = 4.595\tabcellsep ?? 2 = 3\\ \multicolumn{2}{l}{Hypothesis: The two analytical methods, to determine}\tabcellsep \tabcellsep \\ \multicolumn{2}{l}{the percentage purity of Entecavir monohydrate, are not}\tabcellsep \tabcellsep \\ significantly different.\tabcellsep \tabcellsep \tabcellsep \end{longtable} \par {\small\itshape [Note: H 0 :?? = ?? 0 Against H 1 :?? ? ?? 0]} \caption{\label{tab_23}Table 19 :}\end{figure} \footnote{© 2020 Global Journals} \backmatter \subsection[{Acknowledgement}]{Acknowledgement}\par G. Pulla Reddy College of Pharmacy, Osmania University, Hyderabad, India, supported this research work. We would like to appreciate our allies from this institution who provided their insight, expertise, and comments that greatly assisted and improved this research and its manuscript directly and indirectly. However, they may not consent with all of the elucidations and cessations of this paper.\par We thank Prof. Dr. B. Madhava Reddy, Principal, for his encouragement to involve in practical approaches and to allow us to carry out this research work. His endless support and constructive suggestions have been precious during the entire course of work.\par We are also immensely grateful to the Almighty God for giving us the intellect, strength, determination and power to succeed no matter the challenges we had to face to make this research a success.\par Any errors, if encountered in the future, are our own and should not tarnish the reputations of any of the esteemed persons whose work we took as reference for this research. \begin{bibitemlist}{1} \bibitem[Virology]{b1}\label{b1} \textit{}, Amboss Virology . \url{https://www.amboss.com/us/knowledge/} \bibitem[Fang et al. ()]{b32}\label{b32} \textit{}, Y C Fang , X H Yang , W Z Liu , W M Zhu , Q Gu . \textit{An NMR Study on Entecavir Sodium. Chinese Journal of Magnetic Resonance. China} 2006. 23 (4) p. 523. \bibitem[ Biomedical & Pharmacology Journal ()]{b31}\label{b31} \textit{}, \textit{Biomedical \& Pharmacology Journal} 2008. 1 (2) p. . \bibitem[ Viral Drug Entecavir. Journal of Molecular Structure (2018)]{b9}\label{b9} \textit{}, \textit{Viral Drug Entecavir. Journal of Molecular Structure} 2018 Jul 15. 1164 p. . \bibitem[Kumar and Subrahmanyam ()]{b20}\label{b20} ‘A New Validated Stability-Indicating RP-HPLC Method for the Determination of Entecavir’. B R Kumar , K V Subrahmanyam . \textit{Journal of Global Trends in Pharmaceutical Sciences} 2014. 5 (3) p. . \bibitem[Amboss. Hepatitis B Infection Centers for Disease Control and Prevention (CDC) (2019)]{b0}\label{b0} ‘Amboss. Hepatitis B Infection’. \url{https://www.amboss.com/us/knowledge/Hepatitis\textunderscore B\#xid=OS0I-2\&anker=Z8400c8767de06bd1fa7338aa79959829} \textit{Centers for Disease Control and Prevention (CDC)} 2019 July 23. \bibitem[Amboss (2019)]{b3}\label{b3} \textit{Antiviral agents}, Amboss . \url{https://www.amboss.com/us/knowledge/Antiviral\textunderscore agents} 2019 July 28. \bibitem[Ashraf et al. ()]{b13}\label{b13} M Ashraf , Hmn Shabbir , M M Hayat , J Rahman , S Ejaz , M Iqbal . \textit{Tablet Dosage Form and Spiked Plasma}, 2017. 39 p. . (HPLC Determination of Entecavir in Pure) \bibitem[Yunkyoung et al. (2011)]{b25}\label{b25} ‘Determination of Entecavir in Human Plasma by High Performance Liquid Chromatography with Tandem Mass Spectrometry. Spring Seminar and Conference’. C H Yunkyoung , K O Jungsuk , L E Sangbong , K I Hohyun . \textit{Issue: Korean Pharmaceutical Association Spring Seminar and Conference}, 2011 Apr. p. 281. \bibitem[Sythana et al. ()]{b22}\label{b22} ‘Determination of Entecavir in Human Plasma by LC-MS/MS and Method Validation’. S Sythana , Lavanya , Ask Sankar , P Shanmuga Sundaram , V Ravichandiran . \textit{International Journal of PharmTech Research} 2012. 4 (4) p. . \bibitem[Amritharaj et al. ()]{b28}\label{b28} ‘Development and Validation of UV-Spectrophotometric for the Estimation of Entecavir in Tablet Dosage Form’. V Amritharaj , Kumar Vch , N S Kumar . \textit{Journal of Pharmacy Research} 2011. 4 (4) p. . \bibitem[Bharath]{b27}\label{b27} \textit{Development of New Analytical Methods for Quantitative Estimation of Entecavir}, S A Bharath . (dissertation]. [India]: RGUHS; 2011.191 p) \bibitem[Babu et al. (2019)]{b11}\label{b11} ‘Development of New Spectrometric Method for Estimation of Entecavir Monohydrate in Formulation Using 3-Amino Phenol as Chromogenic Reagent’. N R Babu , Y Padmavathi , P R Kumar , R S Babu , D V Vijaya , A Polker . \textit{Journal of Pharmaceutical Sciences and Research} 2019 Jun 1. 11 (6) p. . \bibitem[Sharma ()]{b5}\label{b5} \textit{Elementary organic spectroscopy, principles and chemical application}, Y R Sharma . 2009. New Delhi, India. \bibitem[Yan et al. (2006)]{b4}\label{b4} ‘Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects’. J H Yan , M Bifano , S Olsen , R A Smith , D Zhang , D M Grasela . \textit{The Journal of Clinical Pharmacology} 2006 Nov. 46 (11) p. . \bibitem[Subbarao et al. ()]{b21}\label{b21} ‘Estimation and Validation of Entecavir in Bulk and Pharmaceutical Dosage Forms by UV Spectrophotometry’. J Subbarao , R Rambabu , S Vidyadhara . \textit{World Journal of Pharmaceutical Sciences} 2014. 4 (10) p. . \bibitem[General_virology#xid=Pn0Wtg&anker=Z8045a0f1e 7deea6f3ab44b70d77653d8 (2019)]{b2}\label{b2} \textit{General\textunderscore virology\#xid=Pn0Wtg\&anker=Z8045a0f1e 7deea6f3ab44b70d77653d8}, 2019 July 25. \bibitem[Guideline ICH. Validation of Analytical Procedures: Text and Methodology Q2 (R1)]{b33}\label{b33} \textit{Guideline ICH. Validation of Analytical Procedures: Text and Methodology Q2 (R1)}, (Geneva) \bibitem[Altaf et al. (2015)]{b18}\label{b18} ‘HPLC Method for Simultaneous Determination of Entecavir and Tenofovir in Human Spiked Plasma and Pharmaceutical Dosage Forms. Lat’. H Altaf , M Ashraf , M M Hayat , A Hussain , N Shahzad , M B Ahmad . \textit{Am. J. Pharm} 2015 Jan 1. 34 (3) . \bibitem[Gurdeep R Chatwal et al. ()]{b6}\label{b6} \textit{Instrumental Methods of Chemical Analysis}, Gurdeep R Chatwal , K Sham , Anand . 2005. Mumbai: Himalaya Publishers. (5 th Edition) \bibitem[Yunhua ()]{b26}\label{b26} ‘Interaction between Entecavir and Bovine Serum Albumin by Molecular Spectroscopy’. W Yunhua . \textit{Journal of South-Central University for Nationalities (Natural Science Edition). China} 2010. (1) p. 11. \bibitem[Swathi et al. ()]{b14}\label{b14} ‘Method Development and Validation for the Estimation of Entecavir in Bulk and Pharmaceutical Dosage Forms by RP-HPLC’. P Swathi , S Vidyadhara , Rlc Sasidhar , K K Chakravarthi . \textit{International Journal of Current Pharmaceutical Research} 2017. 9 (5) p. . \bibitem[Elqudaby et al. (2014)]{b19}\label{b19} ‘Microdetermination of Entecavir Drug in its Pharmaceuticals Forms and in Biological Fluids using Anodic Voltammetry’. H M Elqudaby , H A Hendawy , M A Zayed . \textit{World Journal of Pharmaceutical Research} 2014 Jul 22. 3 (7) p. . \bibitem[Jhankal et al. ()]{b17}\label{b17} ‘Quantification of Antiviral Drug Entecavir in Pharmaceutical Formulation by Voltammetric Techniques’. K K Jhankal , A Sharma , D K Sharma . \textit{Journal of Pharmaceutical Sciences and Research} 2015. 7 (1) p. . \bibitem[Kang et al. (2018)]{b10}\label{b10} ‘Quantitation of Polymorphic Impurity in Entecavir Polymorphic Mixtures using Powder X-Ray Diffractometry and Raman Spectroscopy’. Y Kang , Z Shao , Q Wang , X Hu , D Yu . \textit{Journal of Pharmaceutical and Biomedical Analysis} 2018 Sep 5. 158 p. . \bibitem[Manoharan and Mohamed (2019)]{b12}\label{b12} ‘Quantitative Determination of Entecavir in Bulk and Tablet Formulation by a Validated Stability-indicating Reversed-phase HPLC Method’. G Manoharan , R A Mohamed . \textit{Journal of Biochemical Technology} 2019 Jan 1. 10 (1) . \bibitem[Ojeda and Rojas (2013)]{b7}\label{b7} ‘Recent Applications In Derivative Ultraviolet/Visible Absorption Spectro photometry’. C B Ojeda , F S Rojas . \textit{Review. Microchemical Journal} 2013 Jan 1. 106 p. . \bibitem[Challa et al. (2011)]{b24}\label{b24} ‘Rihana parveen S. LC-ESI-MS/MS Method for the Quantification of Entecavir in Human Plasma and its Application to Bioequivalence Study’. B R Challa , B Z Awen , B R Chandu . \textit{Journal of Chromatography B} 2011 Apr 1. 879 (11-12) p. . \bibitem[Rizwana et al.]{b8}\label{b8} B F Rizwana , J C Prasana , C S Abraham , S Muthu . \textit{Spectroscopic Investigation, Hirshfeld Surface Analysis and Molecular Docking Studies on Anti}, \bibitem[Lele and Dalvi ()]{b16}\label{b16} ‘Simultaneous Estimation of Benzyl Chloride and Benzyl Bromide in Entecavir by using High Performance Liquid Chromatography’. V V Lele , U P Dalvi . \textit{World Journal of Pharmaceutical Research} 2016. 5 (10) p. . \bibitem[Kumar and Raju]{b30}\label{b30} \textit{Spectrophotometric Estimation of Entecavir in Pharmaceutical Formulations}, V K Kumar , N A Raju . \bibitem[Malipatil et al. (2012)]{b23}\label{b23} \textit{UV-Spectrophotometric Estimation of Entecavir in Tablet Dosage Form. Pharma Science Monitor}, S M Malipatil , B S Athanikar , M Dipali . 2012 Jul 1. 3 p. . \bibitem[Elzaher et al. (2016)]{b15}\label{b15} \textit{Validated Spectrometric Determination of Penciclovir and Entecavir in Bulk and in Pharmaceutical Preparations. Bulletin of Faculty of Pharmacy}, A A Elzaher , M A Fouad , O M Elhoussini , Y E Behery . 2016 Dec 1. 54 p. . Cairo University \bibitem[Dalmora et al. ()]{b29}\label{b29} ‘Validation of a Stability-Indicating RP-HPLC Method for the Determination of Entecavir in Tablet Dosage Form’. S L Dalmora , M D Sangoi , D R Nogueira , L M Silva . \textit{Journal of AOAC International. Brazil} 2010. 93 (2) p. . \end{bibitemlist} \end{document}